title: Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.
abstract: Both conventional and new anticancer drugs can frequently cause adverse cardiovascular effects, which can span from subclinical abnormalities to serious life-threatening and sometimes fatal events. This review examines the principal basic and clinical elements that may be of profit to identify, prevent and treat such toxicities. Clearly, the accomplishment of such objectives requires the strong commitment and cooperation of different professional figures including, but not limited to, pharmacologists, oncologists and cardiologists. The aspect of anticancer drug cardiotoxicity seems to be somehow underestimated, mainly due to inadequate reporting of adverse reactions from oncology drugs in the post-marketing setting. Thus, the implementation of pharmacovigilance is indispensable to rapidly and fully assess the safety of newer agents in real-life patients.
authors: Department of Cardiology, Policlinico P. Giaccone, University of Palermo, Via del Vespro 129, 90127, Palermo, Italy. bonuraff@libero.it
authors: Francesca
authors: F
authors: Bonura
authors: Daniela
authors: D
authors: Di Lisi
authors: Salvatore
authors: S
authors: Novo
authors: Natale
authors: N
authors: D'Alessandro
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D002309:Cardiology / Q000379:methods* / Q000639:trends; D054715:Cardiotoxins / Q000009:adverse effects* / Q000633:toxicity*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000628:therapy*; D002319:Cardiovascular System / Q000187:drug effects / Q000473:pathology; D006801:Humans; D059232:Laboratory Personnel / Q000639:trends; D008495:Medical Oncology / Q000379:methods* / Q000639:trends; D010600:Pharmacology / Q000379:methods* / Q000639:trends; D010819:Physician's Role; D024382:Professional Role; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D054715:Cardiotoxins